Médecine

Paramédical

Autres domaines


S'abonner

Hair disorders in cancer survivors - 12/04/19

Doi : 10.1016/j.jaad.2018.03.056 
Azael Freites-Martinez, MD a, Jerry Shapiro, MD b, Corina van den Hurk, PhD c, Shari Goldfarb, MD d, Joaquin J. Jimenez, MD e, Anthony M. Rossi, MD a, Ralf Paus, MD, FRSB f, g, Mario E. Lacouture, MD a,
a Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 
d Breast Cancer Medicine Service, Department of Medicine, Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center, New York, New York 
b The Ronald O. Perelman Department of Dermatology, New York University School of Medicine, New York, New York 
c Department of Research, Netherlands Comprehensive Cancer Organization, Utrecht, the Netherlands 
e Department of Dermatology and Cutaneous Surgery, Miller School of Medicine, University of Miami, Miami, Florida 
f Dermatology Research Centre, University of Manchester, and the National Institute of Health Research Manchester Biomedical Research Centre, Manchester, United Kingdom 
g National Institute of Health Research Manchester Biomedical Research Centre, Manchester, United Kingdom 

Correspondence to: Mario E. Lacouture, MD, Dermatology Service, Memorial Sloan Kettering Cancer Center, 60th St Outpatient Center, Ste 407, Rm 4312, 16 E 60th St, New York, NY 10022.Dermatology ServiceMemorial Sloan Kettering Cancer Center60th St Outpatient CenterSte 407, Rm 4312, 16 E 60th StNew YorkNY10022

Abstract

With increasing survival rates across all cancers, survivors represent a growing population that is frequently affected by persistent or permanent hair growth disorders as a result of systemic therapies, radiotherapy, surgical procedures, and therapeutic transplants. These hair disorders include persistent chemotherapy-induced alopecia, persistent radiotherapy-induced alopecia, endocrine therapy–induced alopecia and hirsutism, postsurgery alopecia and localized hypertrichosis, and persistent stem cell transplantation and targeted therapy-induced alopecia. The information contained in this continuing medical education series should facilitate a better understanding on hair disorders in cancer survivors so that adequate support and therapies may be provided.

Le texte complet de cet article est disponible en PDF.

Key words : alopecia, cancer survivors, cancer therapy, endocrine therapy, hirsutism, hypertrichosis, persistent alopecia, persistent chemotherapy-induced alopecia, persistent radiotherapy-induced alopecia, quality of life, therapeutic transplants

Abbreviations used : AE, CTCAE v5.0, eHFSC, EIA, ET, pCIA, pRIA, QoL


Plan


 Reprints not available from the authors.
 Supported in part by National Institutes of Health/National Cancer Institute Cancer Center support grant P30 CA008748. Dr Lacouture is supported by the RJR Oncodermatology Fund. Dr Freites-Martinez is partially supported by Beca Excelencia, Academia Española de Dermatología y Venereología–Fundación Piel Sana. Dr Paus is supported by the National Institute of Health Research Manchester Biomedical Research Centre.
 Dr Shapiro has been a consultant for Aclaris, Samumed, Incyte, Replicel Life Sciences, and Shook, Hardy, and Bacon LLP, who represent Sanofi Aventis US LLC. Dr Goldfarb has a speaking, consultant, or advisory role with Adgero Biopharmaceuticals, AMAG Pharmaceuticals, Procter and Gamble, and Valeant women's health pharmaceuticals. Dr Rossi is a consultant for Cutera and Vivscal. Dr Paus has a speaking, consultant, or advisory role with Giuliani/Italy, Unilever/UK, Reckitt Benkiser/UK, and Shiseido/Japan. Dr Lacouture has a speaking, consultant, or advisory role with Abbvie, Quintiles, Boehringer Ingelheim, Legacy, AstraZeneca Pharmaceuticals, Legacy Healthcare, Foamix, Adgero Bio Pharmaceuticals, Janssen R&D, Novartis, Paxman, and Novocure, and also receives research grants from Berg Veloce, US Biotest, and Bristol-Myers Squibb. Drs Freites-Martinez, van den Hurk, and Jimenez have no conflicts of interest to disclose.
 Date of release: May 2019
 Expiration date: May 2022


© 2018  American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 80 - N° 5

P. 1199-1213 - mai 2019 Retour au numéro
Article précédent Article précédent
  • JAAD Game Changers: Acquired cold urticaria: Clinical features, particular phenotypes, and disease course in a tertiary care center cohort
  • Eden Lake
| Article suivant Article suivant
  • Answers to CME examination

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement ou un achat à l’unité.

Déjà abonné à cette revue ?

;

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.